Aim of our study is to examine some aspects of the relationship between pharmacokinetics and pharmacodynamics of Propafenon that are important as far as its current use is concerned. Orally administered Propafenon is largely absorbed and easily metabolized by the liver. Bioavailability is on the average 50%. Ninety per cent of the administered dose is eliminated in the feces and in the urine in about 60 hours. Because of the lack of a good correlation between chronically administered doses and plasmatic concentration, we tried to see whether the peak concentration after administration of a single dose could predict in some way the response of the patients arrhythmia. So far we do not have a clear cut answer to this question, which probably requires a different, more complex approach to the relations between pharmacokinetics, plasmatic levels and therapeutic range of an antiarrhythmic drug.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Stem Cell Therapy Modulates Molecular Cues of Vasogenic Edema Following Ischemic Stroke: Role of Sirtuin-1 in Regulating Aquaporin-4 Expression.
Stem Cell Rev Rep
January 2025
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gandhinagar, Gujarat, India.
Background: Conventional post-stroke edema management strategies are limitedly successful as in multiple cases of hemorrhagic transformation is being reported. Clinically, acute-ischemic-stroke (AIS) intervention by endovascular mesenchymal stem cells (MSCs) have shown benefits by altering various signaling pathways. Our previous studies have reported that intra-arterial administration of 1*10 MSCs (IA-MSCs) were beneficial in alleviating post-stroke edema by modulating PKCδ/MMP9/AQP4 axis and helpful in preserving the integrity of blood-brain-barrier (BBB).
View Article and Find Full Text PDFTherapeutical potential of natural products in treatment of pancreatic cancer: a review.
Mol Biol Rep
January 2025
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Pancreatic cancer remains as global health challenge, ranking as the seventh leading cause of cancer-related deaths worldwide with high mortality rates and a low five-year survival rate. Despite advancements in conventional therapies, including surgery, chemotherapy, and radiation, the overall survival rates for pancreatic cancer patients have shown minimal improvement. Consequently, there is an urgent need for alternative therapeutic strategies.
View Article and Find Full Text PDFEpstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications.
Med Oncol
January 2025
School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Penang, Malaysia.
Nasopharyngeal carcinoma (NPC) is a distinctive epithelial cancer closely associated with Epstein-Barr Virus (EBV) infection, posing significant challenges in diagnosis and treatment due to its resistance to conventional therapies and high recurrence rates. Current therapies, including radiotherapy and chemotherapy, exhibit limited efficacy, particularly in recurrent or metastatic cases, highlighting the urgent need for novel therapeutic strategies. Targeting EBV oncoproteins, such as Epstein-Barr Virus encoded Nuclear Antigen 1 (EBNA1), Latent Membrane Protein 1 (LMP1), and Latent Membrane Protein 2 (LMP2), presents a promising therapeutic avenue in NPC treatment.
View Article and Find Full Text PDFInvestigation of the antibacterial activity, cytotoxicity, and effects on enamel and composite resin of mouthwash formulations prepared with three different Boron compounds.
Clin Oral Investig
January 2025
Professor, Department of Biology, Faculty of Science, Dokuz Eylul University, Izmir, Tr-35340, Turkey.
Objective: This study investigated the use of oral rinse solutions formulated with boron-containing compounds, known for their antibacterial activity, as an alternative to chlorhexidine (CHX).
Material And Method: Boron nitride (BN), boric acid (BA) and sodium borate (SB) were used in the study. BN was used in nanosuspension (BN-NS) due to its low solubility in water.
Optimization of Single Relaxin B-Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases.
J Med Chem
January 2025
Cardio-Vascular and Metabolism, Sanofi R&D, 13 quai Jules Guesde, Vitry sur Seine 94400, France.
Peptide , a C18 fatty acid-modified single-chain relaxin analogue, was recently identified as a potent, selective, and long-lasting relaxin family peptide receptor 1 (RXFP1) agonist. Further advanced pharmacokinetic profiling of this compound highlighted elevated levels of oxidative metabolism occurring in dogs and mini pigs but only marginally in rats. This study aimed to design long-lasting relaxin analogues with increased stability against metabolic oxidation while securing subnanomolar RXFP1 potency.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!